查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1433663

眼科药品市场规模、份额、趋势分析报告：依药物类别、疾病、剂型类型、给药途径、产品类型、产品、地区、细分市场预测，2024-2030年

Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Steroidal drugs, Anti-VEGF Agents), By Disease, By Dosage Form, By Route of Administration, By Product Type, By Product, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

眼科药品市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球眼科药品市场规模将达到655.5亿美元，2023年至2030年复合年增长率为7.80%。

人们对眼疾的认识不断提高，眼科药物需求激增，是推动市场成长的因素。此外，老龄化黄斑部病变、白内障、干眼症、糖尿病视网膜病变和青光眼等眼科疾病的日益普及预计将推动对眼科药物的需求。

根据BrightFocus基金会预计，2021年将有超过300万美国患有青光眼，其中超过270万名患者将患有最常见的青光眼类型—开放性青光眼。此外，美国有 330 万人失明或视力低下。青光眼和失明的主要危险因子包括年龄较大、家族病史、角膜薄和高眼压。这为眼科药物创造了广泛的人口基础，确保了良好的成长。

此外，眼科药品和药物输送公司正在接受财政援助，以促进开发新药技术进步的研究和开发，这可能会推动市场成长。例如，2020 年 6 月，Re-Vana Therapeutics 从 Qubis、ExSight Ventures, LLC、Clarendon Fund Managers、Visionary Ventures 和 Techstart Ventures LLP 获得了 325 万美元的 Pre-A 轮融资。这笔资金筹措将加速 Li-Vana Therapeutics 的 EyeLief 和 OcuLief生物分解性技术的开发，这些技术预计将用于输送小分子和生技药品。

此外，老年人口的增加是眼科药物市场成长的主要驱动力。据 Safe Eyes America 称，眼疾最常见的危险因子是年龄较大、家族病史、糖尿病和高血压。例如，根据美国健康排名2021年高级报告，超过5,400万65岁及以上的成年人居住在美国，占总人口的16.5%。根据黄斑部病变研究，AMD 是 60 岁以上美国失明的第一大原因。

眼科产品的持续监管核准可能会支持市场成长。例如，参天製药株式会社于2022年6月宣布，其治疗干眼症的Diquas LX眼药水已在日本获得生产和销售核准。该眼药水是一种改良的配方，可减少给药频率并提高患者的依从性。

眼科药品市场报告亮点

  • 由于需求增加和副作用较少，抗 VEGF 药物在 2022 年占据最大份额。
  • 由于老龄化黄斑部病变和糖尿病性视网膜病变的盛行率不断上升，视网膜病变将在 2022 年占据最大的市场占有率。
  • 由于局部给药途径将药物递送至局部部位的优势和易用性等因素，局部给药途径在 2022 年占据市场主导地位。
  • 由于眼药水需求不断增长、患者依从性高以及 OTC 产品易于获得，预计到 2022 年，眼药水细分市场将占据最大的市场份额。
  • 由于医疗基础设施的进步、对眼科产品的需求不断增加以及患者人数众多，预计亚太地区在预测期内将出现最快的增长。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章眼科药品市场：变数、趋势、范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 眼科药品市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 价格分析
    • 管道分析
    • 专利到期分析

第四章眼科药物市场：药物类别的估计与趋势分析

  • 2023年及2030年药品类别市场占有率
  • 细分仪表板
  • 按药物类别分類的全球眼科药物市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第五章眼科药品市场：疾病估计与趋势分析

  • 2023年及2030年疾病市场占有率
  • 细分仪表板
  • 全球眼科药物市场（依疾病分类）展望
  • 2018年至2030年市场规模、预测与趋势分析

第六章 眼科用药市场：给药途径预估及趋势分析

  • 2023 年及 2030 年给药途径市场占有率
  • 细分仪表板
  • 按给药途径分類的全球眼科药物市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第七章眼科药品市场：剂型类型的估计与趋势分析

  • 剂型类型市场占有率，2023 年和 2030 年
  • 细分仪表板
  • 按剂型类型分類的全球眼科药品市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第八章眼科药品市场：产品类型估算及趋势分析

  • 2023 年及 2030 年产品类型市场占有率
  • 细分仪表板
  • 按产品类型分類的全球眼科药品市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第九章眼科药品市场：产品评估与趋势分析

  • 2023年及2030年产品市场占有率
  • 细分仪表板
  • 按产品分類的全球眼科药品市场展望
  • 2018年至2030年市场规模、预测与趋势分析

第10章眼科药品市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概述
  • 2018-2030年市场规模及预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十一章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商形势
    • Pfizer Inc.
    • Alcon
    • Novartis AG
    • Bausch Health Companies Inc.
    • Merck &Co., Inc.
    • Regeneron Pharmaceuticals Inc.
    • Allergan（AbbVie Inc）
    • Bayer AG
    • Genentech, Inc.（F. Hoffmann-La Roche Ltd）
    • Nicox
    • Coherus BioSciences
Product Code: GVR-2-68038-010-1

Ophthalmic Drugs Market Growth & Trends:

The global ophthalmic drugs market size is expected to reach USD 65.55 billion by 2030, garnering a CAGR of 7.80% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.

According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.

Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics' EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.

Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA's HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.

Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.

Ophthalmic Drugs Market Report Highlights:

  • Anti-VEGF agents segment held the largest share in 2022 owing to their rising demand and lesser adverse effects
  • Retinal disorders held the largest market share in 2022 owing to the rising prevalence of age-related macular degeneration and diabetic retinopathy
  • The topical route of administration dominated the market in 2022 owing to factors such as the benefits of the topical route as it delivers the drug to the targeted site and ease of use
  • The eye drops segment is expected to hold the largest share in 2022 owing to rising demand for eye drops, high patient compliance, and availability of OTC products
  • Asia Pacific is expected to exhibit the fastest growth over the forecast period due to advancements in healthcare infrastructure, increasing demand for eye products, and a large patient pool

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Disease
    • 1.2.3. Route of Administration
    • 1.2.4. Dosage Type
    • 1.2.5. Product Type
    • 1.2.6. Product
    • 1.2.7. Regional scope
    • 1.2.8. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class and disease outlook
    • 2.2.2. Route of administration and dosage type outlook
    • 2.2.3. Product type and product outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing disease prevalence
      • 3.2.1.2. Strong developmental pipeline
      • 3.2.1.3. Advancement in drug delivery
      • 3.2.1.4. Promising investment scenario
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of blockbuster drugs
  • 3.3. Ophthalmic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
    • 3.3.5. Patent Expiry Analysis

Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Drug Class Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Ophthalmic Drugs Market by Drug Class Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Anti-allergy
      • 4.4.1.1. Anti-allergy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.2. Anti-VEGF Agents
      • 4.4.2.1. Anti-VEGF agents market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.3. Anti-inflammatory
      • 4.4.3.1. Anti-inflammatory market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.3.2. Non-steroidal drugs
      • 4.4.3.2.1. Non-steroidal drugs market estimates and forecasts 2018 to 2030 (USD Billion)
      • 4.4.3.3. Steroids
      • 4.4.3.3.1. Steroids market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.4. Anti- glaucoma
      • 4.4.4.1. Anti- glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.5. Gene and Cell Therapy
      • 4.4.5.1. Gene and cell therapy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 4.4.6. Others
      • 4.4.6.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis

  • 5.1. Disease Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Ophthalmic Drugs Market by Disease Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Dry Eye
      • 5.4.1.1. Dry eye market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.2. Allergies
      • 5.4.2.1. Allergies market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.3. Glaucoma
      • 5.4.3.1. Glaucoma market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.4. Infection
      • 5.4.4.1. Infection market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.5. Retinal Disorders
      • 5.4.5.1. Retinal disorders market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.5.2. Macular Degeneration
      • 5.4.5.2.1. Macular degeneration market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.5.3. Diabetic Retinopathy
      • 5.4.5.3.1. Diabetic retinopathy market estimates and forecasts 2018 to 2030 (USD Billion)
      • 5.4.5.4. Others
      • 5.4.5.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.6. Uveitis
      • 5.4.6.1. Uveitis market estimates and forecasts 2018 to 2030 (USD Billion)
    • 5.4.7. Others
      • 5.4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Ophthalmic Drugs Market by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Topical
      • 6.4.1.1. Topical market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Local Ocular
      • 6.4.2.1. Local ocular market estimates and forecasts 2018 to 2030 (USD Billion)
      • 6.4.2.2. Subconjunctival
      • 6.4.2.2.1. Subconjunctival market estimates and forecasts 2018 to 2030 (USD Billion)
      • 6.4.2.3. Intravitreal
      • 6.4.2.3.1. Intravitreal market estimates and forecasts 2018 to 2030 (USD Billion)
      • 6.4.2.4. Retrobulbar
      • 6.4.2.4.1. Others market estimates and forecasts 2018 to 2030 (USD Billion)
      • 6.4.2.5. Intracameral
      • 6.4.2.5.1. Intracameral market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. Systemic
      • 6.4.3.1. Systemic market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Ophthalmic Drugs Market: Dosage Type Estimates & Trend Analysis

  • 7.1. Dosage Type Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. Global Ophthalmic Drugs Market by Dosage Type Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Gels
      • 7.4.1.1. Gels market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.2. Eye Solutions and Suspensions
      • 7.4.2.1. Eye solutions and suspensions market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.3. Capsules and Tablets
      • 7.4.3.1. Capsules and tablets market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.4. Eye Drops
      • 7.4.4.1. Eye drops market estimates and forecasts 2018 to 2030 (USD Billion)
    • 7.4.5. Ointments
      • 7.4.5.1. Ointments market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 8. Ophthalmic Drugs Market: Product Type Estimates & Trend Analysis

  • 8.1. Product Type Market Share, 2023 & 2030
  • 8.2. Segment Dashboard
  • 8.3. Global Ophthalmic Drugs Market by Product Type Outlook
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 8.4.1. OTC
      • 8.4.1.1. OTC market estimates and forecasts 2018 to 2030 (USD Billion)
    • 8.4.2. Prescription Drugs
      • 8.4.2.1. Prescription drugs market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 9. Ophthalmic Drugs Market: Product Estimates & Trend Analysis

  • 9.1. Product Market Share, 2023 & 2030
  • 9.2. Segment Dashboard
  • 9.3. Global Ophthalmic Drugs Market by Product Outlook
  • 9.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 9.4.1. Branded Drugs
      • 9.4.1.1. Branded drugs market estimates and forecasts 2018 to 2030 (USD Billion)
    • 9.4.2. Generic Drugs
      • 9.4.2.1. Generic drugs market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2023 & 2030
  • 10.2. Regional Market Dashboard
  • 10.3. Global Regional Market Snapshot
  • 10.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 10.5. North America
    • 10.5.1. U.S.
      • 10.5.1.1. Key country dynamics
      • 10.5.1.2. Regulatory framework/ reimbursement structure
      • 10.5.1.3. Competitive scenario
      • 10.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.5.2. Canada
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework/ reimbursement structure
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.6. Europe
    • 10.6.1. UK
      • 10.6.1.1. Key country dynamics
      • 10.6.1.2. Regulatory framework/ reimbursement structure
      • 10.6.1.3. Competitive scenario
      • 10.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.2. Germany
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework/ reimbursement structure
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.3. France
      • 10.6.3.1. Key country dynamics
      • 10.6.3.2. Regulatory framework/ reimbursement structure
      • 10.6.3.3. Competitive scenario
      • 10.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.4. Italy
      • 10.6.4.1. Key country dynamics
      • 10.6.4.2. Regulatory framework/ reimbursement structure
      • 10.6.4.3. Competitive scenario
      • 10.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.5. Spain
      • 10.6.5.1. Key country dynamics
      • 10.6.5.2. Regulatory framework/ reimbursement structure
      • 10.6.5.3. Competitive scenario
      • 10.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.6. Norway
      • 10.6.6.1. Key country dynamics
      • 10.6.6.2. Regulatory framework/ reimbursement structure
      • 10.6.6.3. Competitive scenario
      • 10.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.7. Sweden
      • 10.6.7.1. Key country dynamics
      • 10.6.7.2. Regulatory framework/ reimbursement structure
      • 10.6.7.3. Competitive scenario
      • 10.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.6.8. Denmark
      • 10.6.8.1. Key country dynamics
      • 10.6.8.2. Regulatory framework/ reimbursement structure
      • 10.6.8.3. Competitive scenario
      • 10.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.7. Asia Pacific
    • 10.7.1. Japan
      • 10.7.1.1. Key country dynamics
      • 10.7.1.2. Regulatory framework/ reimbursement structure
      • 10.7.1.3. Competitive scenario
      • 10.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.2. China
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework/ reimbursement structure
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.3. India
      • 10.7.3.1. Key country dynamics
      • 10.7.3.2. Regulatory framework/ reimbursement structure
      • 10.7.3.3. Competitive scenario
      • 10.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.4. Australia
      • 10.7.4.1. Key country dynamics
      • 10.7.4.2. Regulatory framework/ reimbursement structure
      • 10.7.4.3. Competitive scenario
      • 10.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.5. South Korea
      • 10.7.5.1. Key country dynamics
      • 10.7.5.2. Regulatory framework/ reimbursement structure
      • 10.7.5.3. Competitive scenario
      • 10.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.7.6. Thailand
      • 10.7.6.1. Key country dynamics
      • 10.7.6.2. Regulatory framework/ reimbursement structure
      • 10.7.6.3. Competitive scenario
      • 10.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.8. Latin America
    • 10.8.1. Brazil
      • 10.8.1.1. Key country dynamics
      • 10.8.1.2. Regulatory framework/ reimbursement structure
      • 10.8.1.3. Competitive scenario
      • 10.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.8.2. Mexico
      • 10.8.2.1. Key country dynamics
      • 10.8.2.2. Regulatory framework/ reimbursement structure
      • 10.8.2.3. Competitive scenario
      • 10.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.8.3. Argentina
      • 10.8.3.1. Key country dynamics
      • 10.8.3.2. Regulatory framework/ reimbursement structure
      • 10.8.3.3. Competitive scenario
      • 10.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 10.9. MEA
    • 10.9.1. South Africa
      • 10.9.1.1. Key country dynamics
      • 10.9.1.2. Regulatory framework/ reimbursement structure
      • 10.9.1.3. Competitive scenario
      • 10.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.9.2. Saudi Arabia
      • 10.9.2.1. Key country dynamics
      • 10.9.2.2. Regulatory framework/ reimbursement structure
      • 10.9.2.3. Competitive scenario
      • 10.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.9.3. UAE
      • 10.9.3.1. Key country dynamics
      • 10.9.3.2. Regulatory framework/ reimbursement structure
      • 10.9.3.3. Competitive scenario
      • 10.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 10.9.4. Kuwait
      • 10.9.4.1. Key country dynamics
      • 10.9.4.2. Regulatory framework/ reimbursement structure
      • 10.9.4.3. Competitive scenario
      • 10.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 11. Competitive Landscape

  • 11.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 11.2. Company/Competition Categorization
  • 11.3. Vendor Landscape
    • 11.3.1. List of key distributors and channel partners
    • 11.3.2. Key customers
    • 11.3.3. Key company market share analysis, 2023
    • 11.3.4. Pfizer Inc.
      • 11.3.4.1. Company overview
      • 11.3.4.2. Financial performance
      • 11.3.4.3. Product benchmarking
      • 11.3.4.4. Strategic initiatives
    • 11.3.5. Alcon
      • 11.3.5.1. Company overview
      • 11.3.5.2. Financial performance
      • 11.3.5.3. Product benchmarking
      • 11.3.5.4. Strategic initiatives
    • 11.3.6. Novartis AG
      • 11.3.6.1. Company overview
      • 11.3.6.2. Financial performance
      • 11.3.6.3. Product benchmarking
      • 11.3.6.4. Strategic initiatives
    • 11.3.7. Bausch Health Companies Inc.
      • 11.3.7.1. Company overview
      • 11.3.7.2. Financial performance
      • 11.3.7.3. Product benchmarking
      • 11.3.7.4. Strategic initiatives
    • 11.3.8. Merck & Co., Inc.
      • 11.3.8.1. Company overview
      • 11.3.8.2. Financial performance
      • 11.3.8.3. Product benchmarking
      • 11.3.8.4. Strategic initiatives
    • 11.3.9. Regeneron Pharmaceuticals Inc.
      • 11.3.9.1. Company overview
      • 11.3.9.2. Financial performance
      • 11.3.9.3. Product benchmarking
      • 11.3.9.4. Strategic initiatives
    • 11.3.10. Allergan (AbbVie Inc)
      • 11.3.10.1. Company overview
      • 11.3.10.2. Financial performance
      • 11.3.10.3. Product benchmarking
      • 11.3.10.4. Strategic initiatives
    • 11.3.11. Bayer AG
      • 11.3.11.1. Company overview
      • 11.3.11.2. Financial performance
      • 11.3.11.3. Product benchmarking
      • 11.3.11.4. Strategic initiatives
    • 11.3.12. Genentech, Inc. (F. Hoffmann-La Roche Ltd)
      • 11.3.12.1. Company overview
      • 11.3.12.2. Financial performance
      • 11.3.12.3. Product benchmarking
      • 11.3.12.4. Strategic initiatives
    • 11.3.13. Nicox
      • 11.3.13.1. Company overview
      • 11.3.13.2. Financial performance
      • 11.3.13.3. Product benchmarking
      • 11.3.13.4. Strategic initiatives
    • 11.3.14. Coherus BioSciences
      • 11.3.14.1. Company overview
      • 11.3.14.2. Financial performance
      • 11.3.14.3. Product benchmarking
      • 11.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 3 North America ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 4 North America ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 5 North America ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 6 North America ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 7 North America ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 8 North America ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 9 U.S. ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 10 U.S. ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 11 U.S. ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 12 U.S. ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 13 U.S. ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 14 U.S. ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 15 Canada ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 16 Canada ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 17 Canada ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 18 Canada ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 19 Canada ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 20 Canada ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 21 Europe ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 22 Europe ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 23 Europe ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 24 Europe ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 25 Europe ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 26 Europe ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 27 Europe ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 28 Germany ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 29 Germany ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 30 Germany ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 31 Germany ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 32 Germany ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 33 Germany ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 34 UK ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 35 UK ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 36 UK ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 37 UK ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 38 UK ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 39 UK ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 40 France ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 41 France ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 42 France ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 43 France ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 44 France ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 45 France ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 46 Italy ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 47 Italy ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 48 Italy ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 49 Italy ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 50 Italy ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 51 Italy ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 52 Spain ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 53 Spain ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 54 Spain ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 55 Spain ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 56 Spain ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 57 Spain ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 58 Denmark ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 59 Denmark ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 60 Denmark ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 61 Denmark ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 62 Denmark ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 63 Denmark ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 64 Sweden ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 65 Sweden ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 66 Sweden ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 67 Sweden ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 68 Sweden ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 69 Sweden ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 70 Norway ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 71 Norway ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 72 Norway ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 73 Norway ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 74 Norway ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 75 Norway ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 76 Asia Pacific ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 77 Asia Pacific ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 78 Asia Pacific ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 79 Aisa Pacific ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 80 Aisa Pacific ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 81 Aisa Pacific ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 82 Aisa Pacific ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 83 China ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 84 China ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 85 China ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 86 China ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 87 China ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 88 China ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 89 Japan ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 90 Japan ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 91 Japan ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 92 Japan ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 93 Japan ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 94 Japan ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 95 India ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 96 India ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 97 India ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 98 India ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 99 India ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 100 India ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 101 South Korea ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 102 South Korea ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 103 South Korea ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 104 South Korea ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 105 South Korea ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 106 South Korea ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 107 Australia ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 108 Australia ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 109 Australia ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 110 Australia ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 111 Australia ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 112 Australia ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 113 Thailand ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 114 Thailand ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 115 Thailand ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 116 Thailand ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 117 Thailand ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 118 Thailand ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 119 Latin America ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 120 Latin America ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 121 Latin America ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 122 Latin America ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 123 Latin America ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 124 Latin America ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 125 Latin America ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 126 Brazil ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 127 Brazil ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 128 Brazil ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 129 Brazil ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 130 Brazil ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 131 Brazil ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 132 Mexico ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 133 Mexico ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 134 Mexico ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 135 Mexico ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 136 Mexico ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 137 Mexico ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 138 Argentina ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 139 Argentina ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 140 Argentina ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 141 Argentina ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 142 Argentina ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 143 Argentina ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 144 MEA ophthalmic drugs market, by region 2018 - 2030 (USD Billion)
  • Table 145 MEA ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 146 MEA ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 147 MEA ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 148 MEA ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 149 MEA ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 150 MEA ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 151 South Africa ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 152 South Africa ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 153 South Africa ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 154 South Africa ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 155 South Africa ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 156 South Africa ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 157 Saudi Arabia ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 158 Saudi Arabia ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 159 Saudi Arabia ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 160 Saudi Arabia ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 161 Saudi Arabia ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 162 Saudi Arabia ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 163 UAE ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 164 UAE ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 165 UAE ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 166 UAE ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 167 UAE ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 168 UAE ophthalmic drugs market, by product 2018 - 2030 (USD Billion)
  • Table 169 Kuwait ophthalmic drugs market, by drug class 2018 - 2030 (USD Billion)
  • Table 170 Kuwait ophthalmic drugs market, by disease 2018 - 2030 (USD Billion)
  • Table 171 Kuwait ophthalmic drugs market, by route of administration 2018 - 2030 (USD Billion)
  • Table 172 Kuwait ophthalmic drugs market, by dosage type 2018 - 2030 (USD Billion)
  • Table 173 Kuwait ophthalmic drugs market, by product type 2018 - 2030 (USD Billion)
  • Table 174 Kuwait ophthalmic drugs market, by product 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Ophthalmic drugs market: market outlook
  • Fig. 14 Tumor ablation competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Ophthalmic drugs market driver impact
  • Fig. 20 Ophthalmic drugs market restraint impact
  • Fig. 21 Ophthalmic drugs market strategic initiatives analysis
  • Fig. 22 Ophthalmic drugs market: Drug class movement analysis
  • Fig. 23 Ophthalmic drugs market: Drug class outlook and key takeaways
  • Fig. 24 Anti-allergy market estimates and forecast, 2018 - 2030
  • Fig. 25 Anti-VEGF agents estimates and forecast, 2018 - 2030
  • Fig. 26 Anti-inflammatory market estimates and forecast, 2018 - 2030
  • Fig. 27 Anti-glaucoma estimates and forecast, 2018 - 2030
  • Fig. 28 Gene and cell therapy market estimates and forecast, 2018 - 2030
  • Fig. 29 Others estimates and forecast, 2018 - 2030
  • Fig. 30 Ophthalmic drugs market: Disease movement analysis
  • Fig. 31 Ophthalmic drugs market: Disease outlook and key takeaways
  • Fig. 32 Dry eye market estimates and forecast, 2018 - 2030
  • Fig. 33 Allergies estimates and forecast, 2018 - 2030
  • Fig. 34 Glaucoma market estimates and forecast, 2018 - 2030
  • Fig. 35 Infection estimates and forecast, 2018 - 2030
  • Fig. 36 Retinal disorders market estimates and forecast, 2018 - 2030
  • Fig. 37 Uveitis estimates and forecast, 2018 - 2030
  • Fig. 38 Others estimates and forecast, 2018 - 2030
  • Fig. 39 Ophthalmic drugs market: Route of administration movement analysis
  • Fig. 40 Ophthalmic drugs market: Route of administration outlook and key takeaways
  • Fig. 41 Topical market estimates and forecast, 2018 - 2030
  • Fig. 42 Local ocular estimates and forecast, 2018 - 2030
  • Fig. 43 Systemic market estimates and forecast, 2018 - 2030
  • Fig. 44 Ophthalmic drugs market: Dosage type movement analysis
  • Fig. 45 Ophthalmic drugs market: Dosage type outlook and key takeaways
  • Fig. 46 Gels market estimates and forecast, 2018 - 2030
  • Fig. 47 Eye solutions and suspensions estimates and forecast, 2018 - 2030
  • Fig. 48 Capsules and tablets market estimates and forecast, 2018 - 2030
  • Fig. 49 Eye drops estimates and forecast, 2018 - 2030
  • Fig. 50 Ointments market estimates and forecast, 2018 - 2030
  • Fig. 51 Ophthalmic drugs market: Product type movement analysis
  • Fig. 52 Ophthalmic drugs market: Product type outlook and key takeaways
  • Fig. 53 OTC market estimates and forecast, 2018 - 2030
  • Fig. 54 Prescription drugs estimates and forecast, 2018 - 2030
  • Fig. 55 Ophthalmic drugs market: Product movement Analysis
  • Fig. 56 Ophthalmic drugs market: Product outlook and key takeaways
  • Fig. 57 Branded drugs market estimates and forecasts, 2018 - 2030
  • Fig. 58 Generic drugs market estimates and forecasts,2018 - 2030
  • Fig. 59 Global ophthalmic drugs market: Regional movement analysis
  • Fig. 60 Global ophthalmic drugs market: Regional outlook and key takeaways
  • Fig. 61 Global ophthalmic drugs market share and leading players
  • Fig. 62 North America market share and leading players
  • Fig. 63 Europe market share and leading players
  • Fig. 64 Asia Pacific market share and leading players
  • Fig. 65 Latin America market share and leading players
  • Fig. 66 Middle East & Africa market share and leading players
  • Fig. 67 North America: SWOT
  • Fig. 68 Europe SWOT
  • Fig. 69 Asia Pacific SWOT
  • Fig. 70 Latin America SWOT
  • Fig. 71 MEA SWOT
  • Fig. 72 North America, by country
  • Fig. 73 North America
  • Fig. 74 North America market estimates and forecasts, 2018 - 2030
  • Fig. 75 U.S. key country dynamics
  • Fig. 76 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 77 Canada key country dynamics
  • Fig. 78 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 79 Europe
  • Fig. 80 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 81 UK key country dynamics
  • Fig. 82 UK market estimates and forecasts, 2018 - 2030
  • Fig. 83 Germany key country dynamics
  • Fig. 84 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 85 France key country dynamics
  • Fig. 86 France market estimates and forecasts, 2018 - 2030
  • Fig. 87 Italy key country dynamics
  • Fig. 88 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 89 Spain key country dynamics
  • Fig. 90 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 91 Denmark key country dynamics
  • Fig. 92 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 93 Sweden key country dynamics
  • Fig. 94 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 95 Norway key country dynamics
  • Fig. 96 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 97 Asia Pacific
  • Fig. 98 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 99 China key country dynamics
  • Fig. 100 China market estimates and forecasts, 2018 - 2030
  • Fig. 101 Japan key country dynamics
  • Fig. 102 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 103 India key country dynamics
  • Fig. 104 India market estimates and forecasts, 2018 - 2030
  • Fig. 105 Thailand key country dynamics
  • Fig. 106 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 107 South Korea key country dynamics
  • Fig. 108 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 109 Australia key country dynamics
  • Fig. 110 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 111 Latin America
  • Fig. 112 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 113 Brazil key country dynamics
  • Fig. 114 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 115 Mexico key country dynamics
  • Fig. 116 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 117 Argentina key country dynamics
  • Fig. 118 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 119 Middle East and Africa
  • Fig. 120 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 121 South Africa key country dynamics
  • Fig. 122 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 123 Saudi Arabia key country dynamics
  • Fig. 124 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 125 UAE key country dynamics
  • Fig. 126 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 127 Kuwait key country dynamics
  • Fig. 128 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 129 Market share of key market players- Ophthalmic drugs market